Abstract
Antibodies to amyloid β protein (Aβ) are present naturally or after Aβ vaccine therapy in human plasma. To clarify their clinical role, we examined plasma samples from 113 patients with Alzheimer's disease (AD) and 205 normal controls using the tissue amyloid plaque immunoreactivity (TAPIR) assay. A high positive rate of TAPIR was revealed in AD (45.1%) and age-matched controls (41.2%), however, no significance was observed. No significant difference was observed in the MMS score or disease duration between TAPIR-positive and negative samples. TAPIR-positive plasma reacted with the Aβ40 monomer and dimer, and the Aβ42 monomer weakly, but not with the Aβ42 dimer. TAPIR was even detected in samples from young normal subjects and young Tg2576 transgenic mice. Although the Aβ40 level and Aβ40/42 ratio increased, and Aβ42 was significantly decreased in plasma from AD groups when compared to controls, no significant correlations were revealed between plasma Aβ levels and TAPIR grading. Thus an immune response to Aβ40 and immune tolerance to Aβ42 occurred naturally in humans without a close relationship to the Aβ burden in the brain. Clarification of the mechanism of the immune response to Aβ42 is necessary for realization of an immunotherapy for AD.
| Original language | English |
|---|---|
| Pages (from-to) | 169-179 |
| Number of pages | 11 |
| Journal | Brain Research |
| Volume | 1219 |
| DOIs | |
| Publication status | Published - Jul 11 2008 |
Fingerprint
Keywords
- Aβ
- Alzheimer's disease
- Amyloid
- Antibodies
- Plasma
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology
- Developmental Biology
- Molecular Biology
Cite this
Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls. / Xu, Wuhua; Kawarabayashi, Takeshi; Matsubara, Etsuro; Deguchi, Kentaro; Murakami, Tetsuro; Harigaya, Yasuo; Ikeda, Masaki; Amari, Masakuni; Kuwano, Ryozo; Abe, Koji; Shoji, Mikio.
In: Brain Research, Vol. 1219, 11.07.2008, p. 169-179.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls
AU - Xu, Wuhua
AU - Kawarabayashi, Takeshi
AU - Matsubara, Etsuro
AU - Deguchi, Kentaro
AU - Murakami, Tetsuro
AU - Harigaya, Yasuo
AU - Ikeda, Masaki
AU - Amari, Masakuni
AU - Kuwano, Ryozo
AU - Abe, Koji
AU - Shoji, Mikio
PY - 2008/7/11
Y1 - 2008/7/11
N2 - Antibodies to amyloid β protein (Aβ) are present naturally or after Aβ vaccine therapy in human plasma. To clarify their clinical role, we examined plasma samples from 113 patients with Alzheimer's disease (AD) and 205 normal controls using the tissue amyloid plaque immunoreactivity (TAPIR) assay. A high positive rate of TAPIR was revealed in AD (45.1%) and age-matched controls (41.2%), however, no significance was observed. No significant difference was observed in the MMS score or disease duration between TAPIR-positive and negative samples. TAPIR-positive plasma reacted with the Aβ40 monomer and dimer, and the Aβ42 monomer weakly, but not with the Aβ42 dimer. TAPIR was even detected in samples from young normal subjects and young Tg2576 transgenic mice. Although the Aβ40 level and Aβ40/42 ratio increased, and Aβ42 was significantly decreased in plasma from AD groups when compared to controls, no significant correlations were revealed between plasma Aβ levels and TAPIR grading. Thus an immune response to Aβ40 and immune tolerance to Aβ42 occurred naturally in humans without a close relationship to the Aβ burden in the brain. Clarification of the mechanism of the immune response to Aβ42 is necessary for realization of an immunotherapy for AD.
AB - Antibodies to amyloid β protein (Aβ) are present naturally or after Aβ vaccine therapy in human plasma. To clarify their clinical role, we examined plasma samples from 113 patients with Alzheimer's disease (AD) and 205 normal controls using the tissue amyloid plaque immunoreactivity (TAPIR) assay. A high positive rate of TAPIR was revealed in AD (45.1%) and age-matched controls (41.2%), however, no significance was observed. No significant difference was observed in the MMS score or disease duration between TAPIR-positive and negative samples. TAPIR-positive plasma reacted with the Aβ40 monomer and dimer, and the Aβ42 monomer weakly, but not with the Aβ42 dimer. TAPIR was even detected in samples from young normal subjects and young Tg2576 transgenic mice. Although the Aβ40 level and Aβ40/42 ratio increased, and Aβ42 was significantly decreased in plasma from AD groups when compared to controls, no significant correlations were revealed between plasma Aβ levels and TAPIR grading. Thus an immune response to Aβ40 and immune tolerance to Aβ42 occurred naturally in humans without a close relationship to the Aβ burden in the brain. Clarification of the mechanism of the immune response to Aβ42 is necessary for realization of an immunotherapy for AD.
KW - Aβ
KW - Alzheimer's disease
KW - Amyloid
KW - Antibodies
KW - Plasma
UR - http://www.scopus.com/inward/record.url?scp=45849141567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45849141567&partnerID=8YFLogxK
U2 - 10.1016/j.brainres.2008.02.060
DO - 10.1016/j.brainres.2008.02.060
M3 - Article
C2 - 18534566
AN - SCOPUS:45849141567
VL - 1219
SP - 169
EP - 179
JO - Brain Research
JF - Brain Research
SN - 0006-8993
ER -